• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Janux Therapeutics Inc (NQ: JANX )

    55.28 -0.59 (-1.06%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Janux Therapeutics Inc

    < Previous 1 2 3 Next >
    Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
    Via Benzinga
    Navigating 5 Analyst Ratings For Janux Therapeutics
    Via Benzinga
    Analyst Expectations For Janux Therapeutics's Future
    Via Benzinga
    JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
    JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
    GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
    Via Benzinga
    UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    The Latest Analyst Ratings For Janux Therapeutics
    Via Benzinga
    3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
    Although fraught with risk, these biotech exposures bring enormous upside potential. 
    Via Talk Markets
    Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Analyst Ratings For Janux Therapeutics
    Via Benzinga
    JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
    JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Take the Money and Run: 3 Overbought Stocks to Sell ASAP
    Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. 
    Via InvestorPlace
    A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
    Via Benzinga
    Why Janux Therapeutics Stock Is Crushing It This Week
    Janux's silence about a potential acquisition deal could be golden. 
    Via The Motley Fool
    Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
    Via Benzinga
    These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
    These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
    Via InvestorPlace
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
    Via Benzinga
    Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
    Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The... 
    Via Benzinga
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
    U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
    Via Investor's Business Daily
    Why Janux Therapeutics Stock Soared as the Market Sagged Today
    One of the hotter biotech companies on the scene might be changing owners before long. 
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
    Cantor Fitzgerald's coverage on Janux Therapeutics and its TRACTr/TRACir platform targeting diverse tumor antigens and cancer types. Analysts anticipate substantial growth potential driven by JANX007,... 
    Via Benzinga
    JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
    JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    2 Stocks That Have More Than Tripled This Year: Are They Buys?
    Don't jump on the bandwaggon too quickly. 
    Via The Motley Fool
    B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
    Via Benzinga
    5 Stocks That More Than Doubled In February
    U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
    The biotech tantalized investors with a very promising data update. 
    Via The Motley Fool
    Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
    Via Benzinga
    TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
    The company reported in-line sales for the fourth quarter, but shares soared by double digits. 
    Via Investor's Business Daily
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.